Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor

Imatinib, an orally administered protein-tyrosine kinase inhibitor (TKI) is indicated for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). Severe hepatotoxicity associated with imatinib is rare, and relationship to polymorphism of uridine diphosphate glucuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Saif, Muhammad Wasif, Smith, Melissa Hennessey, Maloney, Antonia, Diasio, Robert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049570/
https://www.ncbi.nlm.nih.gov/pubmed/27708529
http://dx.doi.org/10.20524/aog.2016.0053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049570/
https://www.ncbi.nlm.nih.gov/pubmed/27708529
http://dx.doi.org/10.20524/aog.2016.0053

Ejemplares similares